AGILE SCIENCES, INC.
Novel aminoimidazole (AI) small molecules that inhibit bacterial response regulator proteins to sensitize multidrug-resistant bacteria to antibiotics
- Sector
- Biotech
- Headquarters
- Raleigh, NC
- Founded
- 2007
- Latest Form D
- $1M, May 2020
- Total capital
- $7.6M
- Federal grants
- $3.8M
- 6 awards · 2014–2016
- Rank in peer group#252 of 514
- Private capital raised
- $1M
- 1 Form D · last May 2020
- 77 months since last filing
- Federal contracts
- $2.7M
- 1 award · Health and Human S
- Rank in Biotech#116 of 4373
- Granted patents
- 0
- 2 pending
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$1M
- Federal grantHealth and Human S · Phase II · Small molecules as antibiotic potentiating agents against multi-drug resistant Gram-negative infections$597K
- Federal grantHealth and Human S · Phase I · Small Molecule Antibiotic Potentiators for Drug-Resistant Bacteria$294K
- Federal grantHealth and Human S · Phase II · Development of novel anti-biofilm compounds for treating chronic wounds$833K
- Federal contractHealth and Human S · Igf::ot::igf Targeting Therapeutics Development To Relieve Bottlenecks: Optimizing Lead Therapeutic Compounds Against Infectious Pathogens$2.7M
- Federal grantHealth and Human S · Phase II · Small molecules as antibiotic potentiating agents against multi-drug resistant Gram-negative infections$641K
- Federal grantHealth and Human S · Phase II · Anti-biofilm agents for the treatment of pulmonary infection in cystic fibrosis p$826K
Show 1 earlier federal award
- Federal grantHealth and Human S · Phase II · Development of novel anti-biofilm compounds for treating chronic wounds$635K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
65months
from AGILE SCIENCES, INC.’s first federal award to its first private round.
- First federal award · Dec 2014
- Health and Human S · $635K
- First Form D · May 2020
- $1M · 1st Form D
- Awards before first raise
- 7 awards
An association in public records, not a cause or a prediction.
Standing among 514 peers
Line = medianBiotech · Molecule
- Federal grants#252 · top 49%
- Linked publications#68 · top 13%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Bill CulpepperDirectorNamed in SEC Form D filings
- Christian MelanderExecutive Officer, DirectorNamed in SEC Form D filings
- David LaVanceDirectorNamed in SEC Form D filings
- Harry GarlandDirectorNamed in SEC Form D filings
- John CavanaghExecutive Officer, DirectorNamed in SEC Form D filings
- Keith StonebackDirectorNamed in SEC Form D filings
Show all 9 people
- Malcolm ThomasExecutive Officer, DirectorNamed in SEC Form D filings
- Stephen BrandExecutive OfficerNamed in SEC Form D filings
- Steven YoungDirectorNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 2- PendingCompositions Providing Enhanced Antibacterial Activity Against Gram-positive Bacteria And Use ThereofUSPTOApplication 62808900
- Pending2-AMINOIMIDAZOLE-PHENYL Derivatives Useful For Controlling Microbial GrowthUSPTOApplication PCTUS2018021474
Recent research by its founders
- 2-Aminoimidazole Analogs Target PhoP Altering DNA Binding Activity and Affect Outer Membrane Stability in Gram-Negative Bacteria20225 cites
- Bacteriophage-Liposomes Complex, a Bi-therapy System to Target Streptococcus pneumonia and Biofilm: A Research Protocol20211 cites
- Here's to sound action on global hearing health through public health approaches20205 cites
Related companies, and why
- STC BIOLOGICS, INCSimilar federal contract value in Biotech · $2.8M in contracts
- SYNVITROBIO, INC.Similar federal contract value in Biotech · $2.8M in contracts
- EPIBONE, INC.Similar federal contract value in Biotech · $2.8M in contracts
- Amplyx Pharmaceuticals, Inc.Similar federal contract value in Biotech · $2.7M in contracts
- TECHNOVAX INCSimilar federal contract value in Biotech · $2.7M in contracts
- OMICSCRAFT LLCSimilar federal contract value in Biotech · $2.7M in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .